On September 16, 2022 EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological tumors, reported that pre-clinical data from its solid-tumor subcutaneous CAR therapy program will be presented at the virtual 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology hosted by the Center of Excellence in Immunology of the National Cancer Institute from September 15 – 16, 2022 (Press release, EXUMA Biotechnology, SEP 16, 2022, View Source [SID1234619625]). Additionally, EXUMA will participate in the 7th Annual CAR-TCR Summit organized by Hanson Wade from September 19-22, 2022, in Boston.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are encouraged by the progress of EXUMA’s novel cell and gene therapy platforms, which have the potential to address current challenges with cellular immunotherapies and provide for the next generation of CAR and TCR-based therapies. EXUMA is using advanced lentivectors designed to generate novel cellular therapeutics to treat cancer patients without the need for preparative, lymphodepleting chemotherapy. Our goal is to transform cellular immunotherapy by improving efficacy and safety while also reducing its time, cost, and complexity in order to bring these medicines broadly to patients with significant, unmet medical needs," said Sid Kerkar, M.D., VP, R&D, Oncology.
2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology
(ncifrederick.cancer.gov/events/conferences/NCIImmunology2022)
Thursday & Friday, September 15-16, 2022
Participation: Virtual poster presentation with video recording
Title: In vivo generation of tumor-metabolism-regulated HER-2-specific CAR+ cells eradicate established HER2+ gastric carcinomas with the novel subcutaneous route of administration of CD3-directed lentivector-loaded lymphocytes
Presenters: Dr. Fred Vigant and Dr. Sid Kerkar, Vice President, Research & Development, Oncology
Access: View Source
7th Annual CAR-TCR Summit, Engineering a Disease-Free World
(www.car-tcr-summit.com)